ArticleFrontiers in oncology2025
Case Report: Diagnostic challenges in cervical small cell neuroendocrine carcinoma of a reproductive-age woman.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Diagnosis of Rare Cervical Tumors: IECC Classification, HPV Status, and Subtype-Directed Immunohistochemistry, with Treatment Outcomes from a Tertiary Center.Pathogens (Basel, Switzerland) · 2026Article
- Decoding Cervical Neuroendocrine Carcinoma: A Practical Review of Diagnostic Pitfalls, Differential Diagnosis and Molecular Insights.Diagnostics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Small cell neuroendocrine carcinoma of the cervix (SCNEC) is a rare and highly aggressive malignancy with a poor prognosis. We report the case of a 36-year-old nulliparous woman with a history of HPV-18 infection and repeated cytology showing atypical squamous cells of undetermined significance (ASC-US), while multiple biopsies remained negative. She initially underwent surgery for multiple uterine leiomyomas and severe endometriosis. Ten months later, she presented with acute pelvic pain, rectal pressure, and minor vaginal bleeding. Combined hysteroscopy and laparoscopy revealed suspicious lesions, and histopathology with immunohistochemistry confirmed International Federation of Gynecology and Obstetrics (FIGO) stage IVB SCNEC. Postoperatively, she received platinum-based chemotherapy followed by salvage immunotherapy. Despite a transient decline in tumor markers, the disease progressed rapidly, with enlargement and confluence of pelvic lesions and extensive bone metastases, ultimately resulting in death from multiorgan failure. This case highlights the diagnostic challenges, early systemic dissemination, and poor outcomes of SCNEC, underscoring the urgent need for more effective therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.